Day: November 13, 2019

UNIONDALE, N.Y., Nov. 13, 2019 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced the closing of a $635 million commercial real estate mortgage securitization (the “Securitization”). An aggregate of approximately $534 million of investment grade-rated notes were issued (the “Notes”) and Arbor retained subordinate interests in the issuing vehicle of approximately $101 million. The $635 million of collateral includes approximately $124 million of additional capacity to acquire additional loans for a period of up to 180 days from the closing date of the Securitization.The Notes have an initial weighted average spread of approximately 150 basis points over one-month LIBOR, excluding fees and transaction costs. The facility has a three-year replenishment period that allows the principal proceeds from repayments...

HighlightsReported GAAP net loss of $19.9 million, or $0.07 per share, and adjusted net loss(1) of $21.2 million, or $0.08 per share, in the third quarter of 2019 (excluding items listed in Appendix A to this release).Total Adjusted EBITDA(1) of $27.8 million.Secured strong fourth quarter of 2019 to-date spot tanker rates of $38,000 and $30,500 on average per day for Teekay Tankers’ Suezmax and Aframax fleet, an increase of 133 percent and 105 percent, respectively, compared to the third quarter of 2019.Approximately 90 percent of Teekay Tankers’ fleet is currently trading in the spot tanker market; every $5,000 per day increase in spot tanker rates results in approximately $95 million, or $0.35 per share, in additional annual net income.Transitioning away from the current formulaic dividend policy to focus on delevering balance...

FOR IMMEDIATE RELEASEAffimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional SharesHeidelberg, Germany, November 13, 2019 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced public offering of 12,000,000 common shares, at the public offering price of $2.50 per share, and the exercise in full by the underwriters of their option to purchase an additional 1,800,000 common shares. The exercise of the option to purchase additional shares brought the total number of common shares sold by Affimed to 13,800,000 common shares and increased the gross proceeds raised in the offering, before deducting underwriting...

HighlightsGAAP net income attributable to the partners and preferred unitholders of $47.4 million and GAAP net income per common unit of $0.51.Adjusted net income(1) attributable to the partners and preferred unitholders of $50.5 million and adjusted net income per common unit of $0.55 (excluding items listed in Appendix A to this release).Total Adjusted EBITDA(1) of $180.2 million.Took delivery of fourth and fifth, 50 percent-owned ARC7 LNG carrier newbuildings in August 2019 and early-November 2019, respectively; final ARC7 newbuilding expected to deliver in late-November 2019.Bahrain LNG Regasification terminal expected to commence operations before year-end.Fiscal 2019 earnings guidance range revised upwards by 10 percent(2) and today introducing 2020 guidance with earnings per unit projected to increase by over 55 percent(2) from...

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the third quarter ended September 30, 2019.Third Quarter 2019 and Recent Business HighlightsAdvanced MicroLine for the improvement in near vision in patients with presbyopia towards Phase III development;Deferred development activities for the MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief/lubrication) programs;Presented data from the MicroStat Phase III MIST-1 and MIST-2 studies for pharmacologic mydriasis at AAOpt; andSuccessfully completed an underwritten public offering of our common stock in July 2019 with aggregate...

NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent corporate developments.“We have been very active as we continue to progress the development of our pipeline products, including continued work in support of potential EDSIVO™ approval, and the ongoing development of ACER-001,” said Chris Schelling, CEO and Founder of Acer. “We have completed our EDSIVO™ Type A meeting following receipt of the Complete Response Letter (CRL) and are evaluating plans to appeal the decision. At the same time,...

MONACO, Nov. 13, 2019 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: “DLNG”) (“Dynagas Partners” or the “Partnership”), an owner and operator of LNG carriers, today announced that it will release its financial results for the third quarter ended September 30, 2019 after market closes in New York on Thursday, November 21, 2019.The next day, Friday, November 22, 2019 at 10:00 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the earnings results.Conference Call details:Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (877) 553-9962 (US Toll Free Dial In), 0(808) 238-0669 (UK Toll Free Dial In) or +44 (0) 2071928592 (Standard International Dial In). Please quote “Dynagas.”A telephonic replay of the conference...

MALVERN, Pa., Nov. 13, 2019 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the closing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $13.00 per share. Aggregate gross proceeds to TELA were approximately $52.0 million, before underwriting discounts, commissions and other offering expenses.  All shares of common stock were sold by TELA.  TELA’s common stock is listed on The Nasdaq Global Market under the symbol “TELA.” TELA has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price,...

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent –– Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET –BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlights for the third quarter 2019.  The Company’s net loss applicable to common shareholders for the three months ended September 30, 2019 was $2.0 million. As of September 30, 2019 cash and cash equivalents totaled $13.0 million.“The investigators evaluating CYC065, our CDK2/9 inhibitor, as a single agent have reported that a heavily pretreated patient with MCL1 amplified...

BOULDER, Colo., Nov. 13, 2019 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.“Becoming a publicly listed company earlier this year was a transformative milestone for Brickell and we remain confident about the potential of our lead asset, sofpironium bromide, for primary axillary hyperhidrosis,” commented Robert Brown, Chief Executive Officer of Brickell.  “Ten million people in the United States suffer from this disease which can have a negative impact on a patient’s social life, well-being, emotional and mental health.”Business and...